Yagiz Matthew Akiska

Yagiz Matthew Akiska

Auto-generated profile, based on publicly available information

Yagiz Matthew Akiska

School of Medicine and Health Sciences, The George Washington University, DC, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
ADAnjali J D’aMiano
Anjali J D’aMiano
YAYagiz Matthew Akiska
Yagiz Matthew Akiska
JKJack Kollings
Jack Kollings
ABAaron Bao
Aaron Bao
VMVrinda Madan
Vrinda Madan
SKShawn G. Kwatra
Shawn G. Kwatra
In this retrospective study, we investigated the role of baseline IgE levels in predicting the treatment response to dupilumab in patients with prurigo nodularis (PN). Our findings showed that patients with elevated IgE experienced significantly greater relief from pruritus following dupilumab treatment, suggesting that IgE could serve as a biomarker for identifying individuals who are more likely to benefit from treatments that target interleukin (IL)-4 and IL-13. These results support the development of personalized treatment strategies based on inflammatory profiles in patients with PN.

6 February 2023 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
YAYagiz Matthew Akiska
Yagiz Matthew Akiska
RSRachel Schwartz
Rachel Schwartz
IOIzem Ekin Ozavci
Izem Ekin Ozavci
BRBharat Ranganath
Bharat Ranganath

13 January 2026 in International Journal of Dermatology
Verified
Journal Article
Open access
YAYagiz Matthew Akiska
Yagiz Matthew Akiska
IGIsha Gandhi
Isha Gandhi
RARobert Adler
Robert Adler
DFDeena Fayyad
Deena Fayyad
PBPerya Bhagchandani
Perya Bhagchandani
SKShawn G. Kwatra
Shawn G. Kwatra
Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment. This systematic review examines the diagnostic work‐up and therapeutic approaches for CPUO, evaluating the quality of treatment studies using the Strength of Recommendation Taxonomy (SORT) algorithm. Our paper also uniquely integrates a review of potential pathogenic mechanisms. A comprehensive literature search was conducted in PubMed, EMBASE, Ovid MEDLINE, and Cochrane databases through September 2025 using terms including “CPUO,” “chronic idiopathic pruritus,” and “pruritus of unknown origin.” Studies discussing pathogenesis, diagnostic strategies, or treatment were included. Treatment interventions were assessed based on the SORT algorithm. Of 228 identified records, 52 met inclusion criteria: 18 addressing pathogenesis, 5 discussing competing etiological hypotheses, 3 focusing on diagnostic work‐up, 23 on treatment, and 3 on non‐pharmacological therapies. CPUO pathogenesis appears multifactorial, involving Th2 dysregulation, neurogenic factors (JAK1, GRPR, TRPV4), metabolic alterations, and aging‐related immune changes. Current diagnostic approaches emphasize exclusion of systemic, dermatologic, and neurologic causes. Treatment options include topical agents (calcineurin inhibitors, capsaicin), systemic immunomodulators (JAK inhibitors, dupilumab, nemolizumab), neuromodulators (gabapentin, pregabalin), and phototherapy. However, available treatment studies are of low quality, with few randomized controlled trials (RCTs). CPUO remains a challenging condition with unclear pathophysiology and limited high‐quality therapeutic evidence. Further research, particularly RCTs, is needed to establish evidence‐based management strategies.

4 December 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
WLWeiying Lu
Weiying Lu
SYSelina M Yossef
Selina M Yossef
EMEmily Z Ma
Emily Z Ma
JMJaya Manjunath
Jaya Manjunath
YAYagiz M Akiska
Yagiz M Akiska
SKShawn G. Kwatra
Shawn G. Kwatra
In this study, we explored the relationship between itch intensity, sleep disturbance and quality-of-life (QoL) impairment in patients with prurigo nodularis (PN). Using validated assessment tools, we found significant correlations between self-reported itch severity, objective disease measures, and their impact on sleep and QoL. These findings highlight the profound burden of PN on patients’ daily lives and the importance of addressing both itch and sleep disturbances in managing this condition.

14 October 2025 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
YAYagiz Matthew Akiska
Yagiz Matthew Akiska
MBMorgan Byrne
Morgan Byrne
MNMana Nasseri
Mana Nasseri
AKAdeline Koay
Adeline Koay
MHMichael A. Horberg
Michael A. Horberg
NRNatella Rakhmanina
Natella Rakhmanina

18 October 2025 in JID Innovations
Verified
Journal Article
Open access
YAYagiz Matthew Akiska
Yagiz Matthew Akiska
SBShrey Bhatt
Shrey Bhatt
KVKavita Vats
Kavita Vats
SYSelina M. Yossef
Selina M. Yossef
DGDavies Gage
Davies Gage
SKShawn G. Kwatra
Shawn G. Kwatra
Prurigo nodularis (PN) is a chronic, neuroimmune-driven skin disease characterized by intensely pruritic nodules and marked impairment in QOL. Although PN shares inflammatory features with atopic dermatitis and psoriasis, its underlying pathogenesis remains poorly defined. In this study, we performed NanoString-based transcriptomic profiling on lesional skin biopsies from patients with PN (n = 26), those with atopic dermatitis (n = 25), those with psoriasis (n = 15), and healthy controls (n = 12) using a custom neuroinflammation-focused panel. PN demonstrated a unique molecular signature involving neuroimmune activation (TMEM119, S100A10), extracellular matrix remodeling (matrix metalloproteinase 14 gene MMP14, COL6A3), and fibrotic signaling (TGFBR1, ITGB5), with IL-6 and MAPK12 as key inflammatory mediators. Compared with atopic dermatitis, PN displayed reduced T helper 2 signaling but greater neuroinflammatory and fibrotic activity. Relative to psoriasis, PN lacked T helper 17–driven hyperproliferation but showed macrophage and extracellular matrix activation. STRING network analysis also revealed IL-6 and TGF-β signaling as central hubs linking neuroinflammation and fibrosis. These findings establish PN as a distinct inflammatory skin disease at the intersection of neuroimmune dysregulation and tissue remodeling. Our results highlight key pathways that may guide precision therapies beyond current T helper 2–targeted treatments, supporting the development of IL-6, TGF-β, and Jak/signal transducer and activator of transcription–directed strategies in PN. This transcriptomic analysis establishes a framework to guide mechanistic and therapeutic investigations in PN.